| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2016-10-25 |
复牌提示：
2016-10-25 09:09:05 停牌，复牌日期 2016-10-26 00:00:01
|
| 2016-08-04 |
详情>>
股本变动：
变动后总股本8530.68万股
|
| 2016-08-04 |
详情>>
业绩披露：
2016年中报每股收益-0.65美元,归母净利润-5560.4万美元,同比去年增长-65.34%
|
| 2016-05-05 |
详情>>
业绩披露：
2016年一季报每股收益-0.49美元,归母净利润-4158.5万美元,同比去年增长-111.27%
|
| 2016-02-26 |
详情>>
业绩披露：
2015年年报每股收益-0.83美元,归母净利润-6522.2万美元,同比去年增长-24.14%
|
| 2016-02-26 |
详情>>
业绩披露：
2013年年报每股收益-1.2美元,归母净利润-6941.7万美元,同比去年增长-79.63%
|
| 2015-11-05 |
详情>>
业绩披露：
2015年三季报(累计)每股收益-0.63美元,归母净利润-4821.9万美元,同比去年增长-43.44%
|
| 2015-08-06 |
详情>>
业绩披露：
2015年中报每股收益-0.45美元,归母净利润-3363.1万美元,同比去年增长-21.92%
|
| 2015-05-07 |
详情>>
业绩披露：
2015年一季报每股收益-0.28美元,归母净利润-1968.3万美元,同比去年增长-32.18%
|
| 2015-05-05 |
股东大会：
将于2015-05-19召开股东大会
会议内容 ▼▲
- 1. To elect eight directors named in the accompanying proxy statement to our Board of Directors to serve until our next annual meeting of stockholders or until their respective successors are duly elected and qualified.
2. To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice of annual meeting of stockholders.
3. To ratify the appointment by the Audit Committee of our Board of Directors of Grant Thornton LLP as Raptor’s independent registered public accounting firm for the year ending December 31, 2015.
4. To approve the amendment to the Raptor Pharmaceutical Corp. 2010 Stock Incentive Plan, to increase the share reserve available for issuance under the plan by 3,456,620 shares and to make certain other material amendments.
5. To transact such other business as may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2015-03-02 |
详情>>
业绩披露：
2014年年报每股收益-0.83美元,归母净利润-5254万美元,同比去年增长24.31%
|
| 2014-11-06 |
详情>>
业绩披露：
2014年三季报(累计)每股收益-0.54美元,归母净利润-3361.7万美元,同比去年增长41.36%
|
| 2014-08-07 |
详情>>
业绩披露：
2014年中报每股收益-0.44美元,归母净利润-2758.4万美元,同比去年增长31.12%
|
| 2014-06-17 |
股东大会：
将于2014-07-29召开股东大会
会议内容 ▼▲
- 1. To elect eight directors named in the accompanying proxy statement to our Board of Directors to serve until our next annual meeting of stockholders or until their respective successors are duly elected and qualified.
2. To approve, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice of annual meeting of stockholders.
3. To ratify the appointment by the Audit Committee of our Board of Directors of Grant Thornton LLP as Raptor's independent registered public accounting firm for the year ending December 31, 2014.
4. To approve the Raptor Pharmaceutical Corp. 2013 Employee Stock Purchase Plan.
5. To transact such other business as may properly come before the annual meeting or any adjournment or postponement thereof.
|
| 2013-06-07 |
股东大会：
将于2013-07-23召开股东大会
会议内容 ▼▲
- 1. To elect eight directors named herein to our Board of Directors to serve until our next annual meeting of stockholders or until their respective successors are duly elected and qualified.
2. Advisory vote to approve the compensation of the Company's Named Executive Officers, as disclosed in the proxy statement accompanying this notice of annual meeting of stockholders.
3. To ratify the appointment by the Audit Committee of our Board of Directors of Burr Pilger Mayer, Inc. as Raptor's independent registered public accounting firm for the year ending December 31, 2013.
4. To approve the plan amendment to the Raptor Pharmaceutical Corp. 2010 Stock Incentive Plan, to increase the share reserve available for issuance under the plan by 3,000,000 shares, as well as approve other material amendments relating to the administration of the 2010 Stock Incentive Plan, which are more fully described in the proxy statement accompanying this notice of annual meeting of stockholders.
5. To transact such other business as may properly come before the annual meeting or any adjournment or postponement thereof.
|